Gossamer Bio, Inc.

**Signal Note: Perceptive Advisors Initiates GOSS Position** Edelman's entry into Gossamer suggests conviction in the company's pipeline, likely centered on GB004 (a selective S1P1 modulator in Phase 2 for ulcerative colitis/Crohn's disease) or GB1275 (TrkA inhibitor for pain conditions). The $9.7M position timing may reflect upcoming Phase 2 readouts or confidence in oral S1P1 differentiation versus Obermeyer's revoked approval and Gilead's competitive landscape. Key catalysts include UC/CD efficacy data and potential partnership value, though the relatively modest position size suggests measured exposure rather than conviction bet.